购物车
- 全部删除
- 您的购物车当前为空
Claudin-18.2 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with N-6xHis and C-Avi tag. The predicted molecular weight is 13 KDa and the accession number is P56856-2.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
20 μg | ¥ 3,400 | 5日内发货 | |
100 μg | ¥ 9,210 | 5日内发货 |
生物活性 | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
产品描述 | Claudin-18.2 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with N-6xHis and C-Avi tag. The predicted molecular weight is 13 KDa and the accession number is P56856-2. |
种属 | Human |
表达系统 | E. coli |
标签 | N-6xHis, C-Avi |
蛋白编号 | P56856-2 |
别名 | Claudin-18,CLDN18 |
氨基酸序列 | extracellular |
蛋白构建 | extracellular |
分子量 | 13 KDa (reducing condition) |
内毒素 | < 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
缓冲液 | Supplied as a 0.2 μm filtered solution of 20 mM Tris-HCl, 8M Urea, 150 mM NaCl, 5 mM β-ME, pH 8.5. |
存储 | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
研究背景 | Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.